Expression levels of adiponectin receptors are decreased in human endometrial adenocarcinoma tissues

International Journal of Gynecological Pathology

Volumn 31, Issue 4, 2012, Pages 352-357

  Yamauchi, Naoko ^a   Takazawa, Yutaka ^a   Maeda, Daichi ^a   Hibiya, Takashi ^a   Tanaka, Mariko ^a   Iwabu, Masato ^b   Okada Iwabu, Miki ^b   Yamauchi, Toshimasa ^b   Kadowaki, Takashi ^b   Fukayama, Masashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

Adiponectin; AdipoR1; AdipoR2; Endometrial cancer; Histological grade

Indexed keywords

ADIPONECTIN RECEPTOR 1; ADIPONECTIN RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN P53;

ADULT; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS SURGERY;

CARCINOMA, ENDOMETRIOID; CHI-SQUARE DISTRIBUTION; ENDOMETRIAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; RECEPTORS, ADIPONECTIN; RETROSPECTIVE STUDIES;

EID: 84862280667     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e3182469583     Document Type: Article

References (36)

1. Kounelis S, Kapraos N, Kouri E, et al. Immunohistochemical profile of endometrial adenocarcinoma: A sudy of 61 cases and review of the literature. Mod Pathol 2000;13:379-88.
2. Ito K, Utsunomiya H, Yaegshi N, et al. Biological roles of estrogen and progesterone in human endometrial carcinoma- New developments in potential endocrine therapy for endometrial cancer. Endocrine J 2007;54:667-79.
3. Nakamura K, Hongo A, Kodama J, et al. The role of hepatocyte growth factor activator inhibitor (HAI)-1 and HAI-2 in endometrial cancer. Int J Cancer 2011;128:2613-24.
4. Hoshimoto K, Yamauchi N, Takazawa Y, et al. CD44 variant 6 in endometrioid carcinoma of the uterus: its expression in the adenocarcinoma component is an independent prognostic marker. Pathol Res Pract 2003;199:71-7.
5. Soliman PT, Wu D, Tortolero-Luna G, et al. Association between adiponectin, insulin resistance, and endometrial cancer. Cancer 2006;106:2376-81.
6. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocrine Rev 2005;26:439-51.
7. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest 2006;116:1784-92.
8. Brakenhielm E, Veitonmaki N, Cao R, et al. Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci 2004;101:2476-81.
9. Ogunwobi OO, Beales ILP. Globular adiponectin, acting via adiponectin receptor-1 inhibits leptin-stimulated oesophageal adenocarcinoma cell proliferation. Mol Cell Endocrinol 2008; 285:43-50.
10. Ishikawa M, Kitayama J, Yamauchi T, et al. Adiponectin Inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 2007;98:1120-7.
11. Ishikawa M, Kitayama J, Kazama S, et al. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005;11:466-72.
12. Wei EK, Giovannucci E, Fuchs CS, et al. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005;97:1688-94.
13. Mantzoros C, Petridou E, Dessypris N, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-7.
14. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004;89:1160-3.
15. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 2003;423:762-9.
16. Luo XH, Guo LJ, Yuan LQ, et al. Adiponectin stimulates human osteoblast proliferation and differentiation via the MAPK signaling pathway. Exp Cell Res 2005;309:99-109.
17. Fasshauer M, Klein J, Kralisch S, et al. Growth hormone is a positive regulator of adiponectin receptor 2 in 3T3-L1 adipocyte. FEBS Lett 2004;558:27-32.
18. Kharroubi I, Rasschaert J, Eizirik DL, et al. Expression of adiponectin receptors in pancreatic b cells. Biochem Biophys Res Commun 2003;312:1118-22.
19. Takahata C, Miyoshi Y, Irahara N, et al. Demonstration of adiponectin receptor 1 and 2 mRNA expression in human breast cancer cells. Cancer Lett 2007;250:229-36.
20. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. Biochem Biophys Res Commun 2006;340:1158-66.
21. Cong L, Gasser J, Zhao J, et al. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95-2. Endocrine Relat Cancer 2007;14: 713-20.
22. Scully RE, Bonfiglio TA, Kurman RJ. WHO's histological typing of female genitalerlag, 2003.
23. Maeda D, Ota S, Takazawa Y, et al. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Modern Pathol 2009; 22:824-32.
24. Barresi V, Grosso M, Giuffre G, et al. The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol 2009;62:705-9.
25. Zannoni GF, Vellone VG, Arena V, et al. Does high-grade endometrioid carcinoma (grade 3 FIGO) belong to type I or type II endometrial cancer? Virchows Arch 2010;457:27-34.
26. Barb D, Williams CJ, Neuwirth AK, et al. Adiponectin in relation to malignancies: A review of existing basic research and clinical evidence. Am J Clin Nutr 2007;86:858S-66S.
27. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: Asystemic review. Br J Cancer 2006;94:1221-5.
28. Petridou E, Mantzoros C, Dessypris N, et al. Plasma adiponectin concentrations in relation to endometrial cancer: A case-control study in Greece. J Clin Endocrinol Metab 2003; 88:993-7.
29. Petridou E, Mantzoros C, Dessypris N, et al. Adiponectin in relation to childhood myeloblastic leukaemia. Br J Cancer 2006; 94:156-60.
30. Goktas S, Yilmaz MI, Caglar K, et al. Prostate cancer and adiponectin. Urology 2005;65:1168-72.
31. Srijaipracharoen S, Tangjitgamol S, Tanvanich S, et al. Expression of ER, PR, and Her-2/neu in endometrial cancer: A clinicopathological study. Asian Pacific J Cancer Prev 2010;11: 215-20.
32. Fukuda K, Mori M, Uchiyama M, et al. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998;69:200-5.
33. Jeon YT, Park IA, Kim YB, et al. Steroid receptor expressions in endometrial cancer. Clinical significance and epidemiological implication. Cancer Lett 2006;239:198-204.
34. Suthipintawong C, Wejaranayang C, Vipupinyo C. Prognostic significance of ER, PR, KI-67, c-erbB-2, and p53 in endometrial carcinoma. J Med Assoc Thai 2008;91:1779-85.
35. Ota K, Ito K, Suzuki T, et al. Peroxisome proliferator-activated receptor g and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res 2006;12:4200-8.
36. Takemura Y, Osuga J, Yamauchi T, et al. Expression of adiponectin receptors and its possible implication in the human endometrium. Endocrinology 2006;147:3203-10.